Cited by 770Hepatitis C virus researchLiver physiology and pathologyLiver Disease Diagnosis and Treatment

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Hepatitis C: the clinical spectrum of disease.

Open access

Hoofnagle, J H·1997·Hepatology

Open this paper in CoChat — free account Open PDF

Abstract

Hepatitis C virus (HCV) accounts for approximately 20% of cases of acute hepatitis, 70% of chronic hepatitis, and 30% of end-stage liver disease in the United States. The acute infection has an incubation period of 7 weeks (range, 4-20 weeks) and is symptomatic and icteric in only one third of patients. Serum aminotransferase levels generally increase greater than 10-fold elevated and as symptoms and signs resolve decrease into the normal range. Antibody to HCV is usually but not always present at the time of onset of symptoms. HCV RNA appears in the serum early during the incubation period, increases in titer and peaks at the time of symptoms, and then disappears in resolving disease. Importantly, 85% of patients with acute HCV infection develop chronic infection. In these patients, HCV RNA remains present and in approximately two thirds of patients, aminotransferases remain elevated in the range of 1.5- to 10-fold the upper limit of normal. The course of chronic hepatitis C is variable. Probably fewer than 20% of patients have symptoms and they are usually intermittent, vague, and nonspecific, largely being malaise and easy fatiguability. A small percentage of patients develop extrahepatic manifestations of hepatitis C, including cryoglobulinemia and glomerulonephritis. It is estimated that 20% to 30% of patients with chronic hepatitis C develop cirrhosis, but the process is generally slow and insidious. Once cirrhosis develops, symptoms are more common and the signs of end-stage liver disease can appear with jaundice, weakness, wasting, and gastrointestinal bleeding. Patients with cirrhosis are also at risk for developing hepatocellular carcinoma. Thus, this important liver disease has protean manifestations but is often insidious and can lead to end-stage liver disease despite the presence of few symptoms and signs of illness.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/hep.510260703

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Classification of chronic hepatitis: Diagnosis, grading and staging
Desmet, V. J., Gerber, M. A., Hoofnagle, J. H., Manns, M. P., & Scheuer, P. J. (1994) · Hepatology · doi:10.1002/hep.1840190629 · Cited by 2,591
Detection of Antibody to Hepatitis C Virus in Prospectively Followed Transfusion Recipients with Acute and Chronic Non-A, Non-B Hepatitis
Alter, H. J., Purcell, R. H., Shih, J. W., Melpolder, J. C., Houghton, M., Choo, Q.-L., & Kuo, G. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911303212202 · Cited by 1,658
Clinical Outcomes after Transfusion-Associated Hepatitis C
Tong, M. J., El-Farra, N. S., Reikes, A., & Co, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506013322202 · Cited by 1,191
Long-Term Outcome of Hepatitis C Infection after Liver Transplantation
Gane, E. J., Portmann, B. C., Naoumov, N. V., Smith, H. M., Underhill, J. A., Donaldson, P. T., Maertens, G. G., & Williams, R. L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603283341302 · Cited by 963
Membranoproliferative Glomerulonephritis Associated with Hepatitis C Virus Infection
Johnson, R. J., Gretch, D. R., Yamabe, H., Hart, J., Bacchi, C. E., Hartwell, P., Couser, W. G., Corey, L., Wener, M. H., Alpers, C. E., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302183280703 · Cited by 870
Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease
Houghton, M., Weiner, A. J., Han, J. H., Kuo, G. C., & Choo, Q. (1991) · Hepatology · doi:10.1002/hep.1840140227 · Cited by 862
Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections.
Weiner, A. J., Geysen, H. M., Christopherson, C., Hall, J. E., Mason, T. J., Saracco, G. M., Bonino, F., Crawford, K., Marion, C. D., & Crawford, K. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3468 · Cited by 703
Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis
Seeff, L. B., Buskell‐Bales, Z., Wright, E. C., Durako, S. J., Alter, H. J., Iber, F. L., Hollinger, F. B., Gitnick, G., Knodell, R. G., Perrillo, R. P., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272703 · Cited by 668
PREVALENCE OF ANTIBODIES TO HEPATITIS C VIRUS IN ITALIAN PATIENTS WITH HEPATOCELLULAR CARCINOMA
Colombo, M., Choo, Q. L., Ninno, E. D., Dioguardi, N., Kuo, G. C., Donato, M. F., Tommasini, M., & Houghton, M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91016-7 · Cited by 666
Routes of Infection, Viremia, and Liver Disease in Blood Donors Found to Have Hepatitis C Virus Infection
Conry‐Cantilena, C., VanRaden, M. J., Gibble, J. W., Melpolder, J. C., Shakil, A. O., Viladomiu, L., Cheung, L., DIBISCEGLIE, A., Hoofnagle, J. H., Shih, J. W., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606273342602 · Cited by 627

Show all 47 references

Research works printed but not linked: 6

Serfaty L, Nousbaum JB, Elghouzzi MH, Giral P, Legendre C, Poupon followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494-1500.
Barrera JM, Bruguera M, Guadalupe-Ercilla M, Gil C, Celis R, Gil MP, del Valle Onorato M, et al. Persistent hepatitis C viremia after acute HEPATOLOGY 1995;21:725-729.
Morales TG, Sampliner RE, Bhattacharyya A, Alter MJ. Liver histology self-limiting posttransfusion hepatitis C. HEPATOLOGY 1995;21:639-644.
Alter MJ, Hadler SC, Judson FN, Mares A, Alexander J, Hu PY, Miller in anti-HCV positive persons with normal or minimally elevated amino- transferases. J Clin Gastroenterol 1995;21:301-305.
Farci P, Alter HJ, Wong D, Miller RH, Shih JW, Jett B, Purcell RH. A non-A, non-B hepatitis. N Engl J Med 1992;327:1906-1911.
Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Don- 1995;123:897-903.

Sorted by citations

Items 301–400 of 770

A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C
Gentile, I., Coppola, N., Pasquale, G. D., Liuzzi, R., D'Armiento, M. R., Lorenzo, M. E. D., Capoluongo, N., Buonomo, A. R., Sagnelli, E., Morisco, F., et al. (2013) · Hepatitis Monthly · doi:10.5812/hepatmon.8352 · Cited by 28
Hepatitis C Lipo-Viro-Particle from Chronically Infected Patients Interferes with TLR4 Signaling in Dendritic Cell
Agaugué, S., Perrin‐Cocon, L., André, P., & Lotteau, V. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000330 · Cited by 28
The Role of Chemokines in Hepatitis C Virus-Mediated Liver Disease
Braß, A., & Brenndörfer, E. D. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15034747 · Cited by 29
Enhanced IL-10 production in response to hepatitis C virus proteins by peripheral blood mononuclear cells from human immunodeficiency virus-monoinfected individuals
Barrett, L., Gallant, M., Howley, C., Bowmer, M. I., Hirsch, G., Peltekian, K. M., & Grant, M. D. (2008) · BMC Immunology · doi:10.1186/1471-2172-9-28 · Cited by 28
Patient Education and Treatment Strategies Implemented at a Pharmacist‐Managed Hepatitis C Virus Clinic
Kolor, B. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.9.1230 · Cited by 28
Activation of endoplasmic reticulum stress response by hepatitis C virus proteins
Ciccaglione, A. R., Costantino, A., Tritarelli, E., Marcantonio, C., Equestre, M., Marziliano, N., & Rapicetta, M. (2005) · Archives of Virology · doi:10.1007/s00705-004-0487-4 · Cited by 28
Ribavirin with or without alpha interferon for chronic hepatitis C
Gluud, L. L., Krogsgaard, K., & Gluud, C. N. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002234 · Cited by 28
Retracted
Point-of-care testing for HCV infection: recent advances and implications for alternative screening.
Parisi, M. R., Soldini, L., Vidoni, G., Mabellini, C., Belloni, T., Brignolo, L., Negri, S., Schlusnus, K., Dorigatti, F., & Lazzarin, A. (2014) · PubMed · Cited by 27
Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titres
Sagnelli, E., Coppola, N., Marrocco, C., Coviello, G., Battaglia, M., Messina, V., Rossi, G., Sagnelli, C., Scolastico, C., & Filippini, P. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.12.027 · Cited by 27
An engineered inhibitor RNA that efficiently interferes with hepatitis C virus translation and replication
Romero‐López, C., Berzal-Herranz, B., Gómez, J., & Berzal‐Herranz, A. (2012) · Antiviral Research · doi:10.1016/j.antiviral.2012.02.015 · Cited by 27
Pyrazolo[1,5-a]pyrimidine-based inhibitors of HCV polymerase
Popovici-Müller, J. V., Shipps, G. W., Rosner, K. E., Deng, Y., Wang, T., Curran, P. J., Brown, M. A., Siddiqui, M. A., Cooper, A. B., Duca, J. S., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.09.087 · Cited by 27
Responses of Nontransformed Human Hepatocytes to Conditional Expression of Full-Length Hepatitis C Virus Open Reading Frame
Tang, W., Lázaro, C. A., Campbell, J. S., Parks, W. T., Katze, M. G., & Fausto, N. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070413 · Cited by 27
Hepatitis C virus core protein transactivates the inducible nitric oxide synthase promoter via NF-κB activation
DELUCAS, S., Bartolomé, J., Amaro, M. M., & Carreno, V. (2003) · Antiviral Research · doi:10.1016/j.antiviral.2003.08.006 · Cited by 27
Longitudinal Evaluation of the Structure of Replicating and Circulating Hepatitis C Virus Quasispecies in Nonprogressive Chronic Hepatitis C Patients
Cabot, B., Martell, M., Esteban, J. I., Pirón, M., Otero, T., Esteban, R., Guàrdia, J., & Gómez, J. (2001) · Journal of Virology · doi:10.1128/jvi.75.24.12005-12013.2001 · Cited by 27
Altered Functionality of Anti-Bacterial Antibodies in Patients with Chronic Hepatitis C Virus Infection
Lamontagne, A., Long, R. E., Comunale, M. A., Hafner, J., Rodemich-Betesh, L., Wang, M., Marrero, J. A., Bisceglie, A. M. D., Block, T. M., & Mehta, A. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064992 · Cited by 26
Completion of Hepatitis C Virus Replication Cycle in Heterokaryons Excludes Dominant Restrictions in Human Non-liver and Mouse Liver Cell Lines
Frentzen, A., Hueging, K., Bitzegeio, J., Friesland, M., Haid, S., Gentzsch, J., Hoffmann, M., Lindemann, D., Zimmer, G., Zielecki, F., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002029 · Cited by 26
Decrease of T-cells exhaustion markers programmed cell death-1 and T-cell immunoglobulin and mucin domain-containing protein 3 and plasma IL-10 levels after successful treatment of chronic hepatitis C
Osuch, S., Laskus, T., Berak, H., Perlejewski, K., Metzner, K. J., Paciorek, M., Radkowski, M., & Cortés, K. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-73137-6 · Cited by 26
European guideline for the management of hepatitis B and C virus infections
Brook, M. G. (2001) · International Journal of STD & AIDS · doi:10.1258/0956462011923930 · Cited by 26
Tobacco and other factors have a negative impact on quality of life in hepatitis C patients
Yamini, D., Basseri, B., Chee, G. M., Arakelyan, A., Enayati, P. J., Tran, T. T., & Poordad, F. F. (2010) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2010.01361.x · Cited by 26
The transmembrane domain of hepatitis C virus E1 glycoprotein induces cell death
Ciccaglione, A. R., Marcantonio, C., Tritarelli, E., Equestre, M., Magurano, F., Costantino, A., Nicoletti, L., & Rapicetta, M. (2004) · Virus Research · doi:10.1016/j.virusres.2004.02.002 · Cited by 26
Hepatic 31 P MRS in rat models of chronic liver disease: assessing the extent and progression of disease
Corbin, I. R., Buist, R. J., Peeling, J., Zhang, M., Uhanova, J., & Minuk, G. Y. (2003) · Gut · doi:10.1136/gut.52.7.1046 · Cited by 26
Pyrrolidine-5,5-trans-lactams. 1. Synthesis and Incorporation into Inhibitors of Hepatitis C Virus NS3/4A Protease
Andrews, D. M., Carey, S. J., Chaignot, H. M., Coomber, B. A., Gray, N. M., Hind, S. L., Jones, P. S., Mills, G., Robinson, J. E., & Slater, M. J. (2002) · Organic Letters · doi:10.1021/ol027013x · Cited by 26
Viral kinetics in the treatment of chronic hepatitis C
Layden‐Almer, J. E., Cotler, S. J., & Layden, T. J. (2006) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2006.00715.x · Cited by 26
Hepatitis C virus: genotype identification and interactions between viral proteases
Žusinaite, E. (2005) · DSpace repository (University of Tartu) · Cited by 26
Laboratory Diagnosis and Monitoring of Viral Hepatitis
Prasidthrathsint, K., & Stapleton, J. T. (2019) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2019.02.007 · Cited by 25
Hyperlipasemia Associated with Hepatitis C Virus
Yoffe, B., Bagri, A. S., Tran, T., Dural, A. T., Shtenberg, K. M., & Khaoustov, V. I. (2003) · Digestive Diseases and Sciences · doi:10.1023/a:1024744613671 · Cited by 25
Mild Cognitive Impairment: Emerging Therapeutics
Sramek, J. J., Veroff, A. E., & Cutler, N. R. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19394 · Cited by 13
An integrated approach identifies IFN-regulated microRNAs and targeted mRNAs modulated by different HCV replicon clones
Bruni, R., Marcantonio, C., Tritarelli, E., Tataseo, P., Stellacci, E., Costantino, A., Villano, U., Battistini, A., & Ciccaglione, A. R. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-485 · Cited by 25
Reconstruction of the evolutionary dynamics of hepatitis C virus subtypes in Montenegro and the Balkan region
Zehender, G., Sorrentino, C., Lai, A., Ebranati, E., Gabanelli, E., Presti, A. L., Vujošević, D., Laušević, D., Terzić, D., Shkjezi, R., et al. (2013) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2013.04.003 · Cited by 24
Hepatitis C and poor quality of life: Is it the virus or the patient?
Abdo, A. A. (2008) · Saudi Journal of Gastroenterology · doi:10.4103/1319-3767.41727 · Cited by 24
A Novel Class of meso -Tetrakis-Porphyrin Derivatives Exhibits Potent Activities against Hepatitis C Virus Genotype 1b Replicons In Vitro
Cheng, Y., Tsou, L. K., Cai, J., Aya, T., Dutschman, G. E., Gullen, E. A., Grill, S. P., Chen, A. P.-C., Lindenbach, B. D., Hamilton, A. D., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01206-09 · Cited by 24
Oligonucleotide-based Strategies to Inhibit Human Hepatitis C Virus
Martinand‐Mari, C., Lebleu, B., & Robbins, I. J. (2003) · Oligonucleotides · doi:10.1089/154545703322860834 · Cited by 24
Influence of Chronic Alcohol Abuse on Hepatitis C Virus Replication
Anand, B. S., & Velez, M. E. (2000) · Digestive Diseases · doi:10.1159/000051390 · Cited by 24
An unbalanced PD-L1/CD86 ratio in CD14++CD16+ monocytes is correlated with HCV viremia during chronic HCV infection
Zheng, J., Liang, H. L., Xu, C., Xu, Q., Zhang, T., Shen, T., & Lu, F. (2014) · Cellular and Molecular Immunology · doi:10.1038/cmi.2013.70 · Cited by 23
Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin
Nachnani, J. S., Rao, G., Bulchandani, D. G., Pandya, P., & Alba, L. M. (2009) · Annals of Hematology · doi:10.1007/s00277-009-0774-y · Cited by 23
Reconstruction of the evolutionary dynamics of the hepatitis C virus 1b epidemic in Turkey
Ciccozzi, M., Ciccaglione, A. R., Presti, A. L., Yalçınkaya, T., Taskan, Z. P., Equestre, M., Costantino, A., Bruni, R., Ebranati, E., Salemi, M., et al. (2011) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2011.02.006 · Cited by 23
Back to the origin of HCV 2c subtype and spreading to the Calabria region (Southern Italy) over the last two centuries: A phylogenetic study
Marascio, N., Ciccozzi, M., Equestre, M., Presti, A. L., Costantino, A., Cella, E., Bruni, R., Liberto, M. C., Pisani, G., Zicca, E., et al. (2014) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2014.06.006 · Cited by 23
Recent advances in prevention and treatment of hepatitis C virus infections
Wang, Q. M., & Heinz, B. A. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7784-8_3 · Cited by 23
Hepatitis C, cryoglobulinemia, and cutaneous vasculitis associated with unusual and serious manifestations
Méndez, P., Saeian, K., Reddy, K. R., Younossi, Z. M., Kerdel, F., Badalamenti, S., Jeffers, L. J., & Schiff, E. R. (2001) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)02622-3 · Cited by 23
α-Interferon Improves Liver Fibrosis in Chronic Hepatitis C
Serejo, F., Costa, A., Oliveira, A. G., Ramalho, F. J., Batista, A., & de Moura, M. C. (2001) · Digestive Diseases and Sciences · doi:10.1023/a:1010649403659 · Cited by 23
Feasibility of Hepatitis C Elimination in China: From Epidemiology, Natural History, and Intervention Perspectives
Zhao, Z., Chu, M., Guo, Y., Yang, S., Abudurusuli, G., Frutos, R., & Chen, T. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.884598 · Cited by 22
Diagnosis and management of chronic liver disease in older people
Fox, M. R., Fox, J., & Davies, M. H. (2010) · Reviews in Clinical Gerontology · doi:10.1017/s0959259810000365 · Cited by 22
Long-Term Persistent GBV-B Infection and Development of a Chronic and Progressive Hepatitis C-Like Disease in Marmosets
Iwasaki, Y., Mori, K., Ishii, K., Maki, N., Iijima, S., Yoshida, T., Okabayashi, S., Katakai, Y., Lee, Y., Saito, A., et al. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00240 · Cited by 22
Integrating Hepatitis C Services into Existing HIV Services: The Experiences of a Sample of U.S. Drug Treatment Units
Strauss, S. M., Astone, J. M., Jarlais, D. C. D., & Hagan, H. (2005) · AIDS Patient Care and STDs · doi:10.1089/apc.2005.19.78 · Cited by 22
Diagnóstico da hepatite C na prática médica: revisão da literatura
Brandão, A. B. D. M., Fuchs, S. C. P. C., Silva, M. A. D. A., & Emer, L. F. (2001) · Revista Panamericana de Salud Pública · doi:10.1590/s1020-49892001000300005 · Cited by 22
Antisense oligonucleotide inhibition of hepatitis C virus genotype 4 replication in HepG2 cells
Awady, M. K. E., Din, N. G. B. E., El-Garf, W., Youssef, S. S., Omran, M. H., Abd, Y. S. E., & Goueli, S. A. (2006) · Cancer Cell International · doi:10.1186/1475-2867-6-18 · Cited by 22
Mutagenesis of hepatitis C virus E1 protein affects its membrane-permeabilizing activity
Ciccaglione, A. R., Costantino, A., Marcantonio, C., Equestre, M., Geraci, A., & Rapicetta, M. (2001) · Journal of General Virology · doi:10.1099/0022-1317-82-9-2243 · Cited by 22
Is autoimmune hepatitis a frequent finding among HCV patients with intense interface hepatitis?
Badiani, R. G. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i29.3704 · Cited by 21
Quality of life, depression, and cytokine patterns in patients with chronic hepatitis C treated with antiviral therapy
Falasca, K., Mancino, P., Ucciferri, C., Dalessandro, M., Manzoli, L., Pizzigallo, E., Conti, C. M., & Vecchiet, J. (2009) · Clinical and investigative medicine · doi:10.25011/cim.v32i3.6110 · Cited by 21
Risk factors for hepatitis C fibrosis: a prospective study of United States veterans* compared with nonveterans
Kayali, Z., Tan, S., Shinkunas, L. A., Voigt, M. D., LaBrecque, D. R., Stapleton, J. T., Brown, K. E., & Schmidt, W. N. (2006) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2006.00764.x · Cited by 21
Evaluation of high-resolution computed tomography and pulmonary function tests in patients with chronic hepatitis C virus infection
Okutan, O., Kartaloğlu, Z., Ïlvan, A., Kutlu, A., Bozkanat, E., & Şilit, E. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i3.381 · Cited by 21
Utility of α-Glutathione S-transferase assessment in chronic hepatitis C patients with near normal alanine aminotransferase levels
Giannini, E. G., Risso, D., Ceppa, P., Botta, F., Chiarbonello, B., Fasoli, A., Malfatti, F., Romagnoli, P., Lantieri, P. B., & Testa, R. (2000) · Clinical Biochemistry · doi:10.1016/s0009-9120(00)00080-1 · Cited by 21
A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States
Strauss, S. M., Astone, J. M., Jarlais, D. D., & Hagan, H. (2003) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2003.08.009 · Cited by 21
Management Strategies for Ribavirin-Induced Hemolytic Anemia in the Treatment of Hepatitis C: Clinical and Economic Implications
Devine, E. B., Kowdley, K. V., Veenstra, D. L., & Sullivan, S. D. (2001) · Value in Health · doi:10.1046/j.1524-4733.2001.45075.x · Cited by 21
Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis
Fontana, R. J., Everson, G. T., Tuteja, S., Vargas, H. E., & Shiffman, M. L. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00002-3 · Cited by 21
Characterization of Hepatitis C Virus Intra- and Intergenotypic Chimeras Reveals a Role of the Glycoproteins in Virus Envelopment
Steinmann, E., Doerrbecker, J., Friesland, M., Riebesehl, N., Ginkel, C., Hillung, J., Gentzsch, J., Lauber, C., Brown, R. J. P., Frentzen, A., et al. (2013) · Journal of Virology · doi:10.1128/jvi.01708-13 · Cited by 20
Hepatitis C Virus: Insights Into Its History, Treatment, Challenges, and Future Directions
Bernal, L. A., & Soti, V. (2023) · Cureus · doi:10.7759/cureus.43924 · Cited by 20
Hepatitis C Virus: Propagation, Quantification, and Storage
Yi, M. (2010) · Current Protocols in Microbiology · doi:10.1002/9780471729259.mc15d01s19 · Cited by 19
Expression of HCV E1 Protein in Baculovirus-Infected Cells: Effects on Cell Viability and Apoptosis Induction
Ciccaglione, A. R., Marcantonio, C., Costantino, A., Equestre, M., & Rapicetta, M. (2003) · Intervirology · doi:10.1159/000069747 · Cited by 20
Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia
Poordad, F., Theodore, D., Sullivan, J., & Grotzinger, K. M. (2011) · Journal of Medical Economics · doi:10.3111/13696998.2011.562266 · Cited by 20
Clinical course and outcome of a nosocomial outbreak of hepatitis C in a urology ward
Pekova, L., Teocharov, P., & Sakarev, A. (2007) · Journal of Hospital Infection · doi:10.1016/j.jhin.2007.06.010 · Cited by 20
Hepatitis C virus-induced liver disease in dialysis patients
Barril, G. (2000) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/15.suppl_8.42 · Cited by 20
Evasion of host immune surveillance by hepatitis C virus: potential roles in viral persistence.
Moorman, J. P., Joo, M., & Hahn, Y. S. (2001) · PubMed · Cited by 20
CUTANEOUS MANIFESTATIONS OF SYSTEMIC INFECTIONS
Cherry, J. D. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4044-6.50069-8 · Cited by 20
Meta‐analysis: combination therapy with interferon‐α 2a/2b and ribavirin for patients with chronic hepatitis C previously non‐responsive to interferon
Miguel, R. S., Guillén‐Grima, F., Hita, J. M. C., & Buti, M. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01328.x · Cited by 20
Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection
Gentile, I., Buonomo, A. R., & Borgia, G. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.940898 · Cited by 19
Evaluation of hepatobiliary ultrasound scores in healthy dogs and dogs with liver diseases
Assawarachan, S. N., Chuchalermporn, P., Maneesaay, P., & Thengchaisri, N. (2019) · Veterinary World · doi:10.14202/vetworld.2019.1266-1272 · Cited by 19
Will prior health insurance authorization for medications continue to hinder hepatitis C treatment delivery in the United States? Perspectives from hepatitis C treatment providers in a large urban healthcare system
Javanbakht, M., Archer, R., & Klausner, J. D. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241615 · Cited by 20
RNA aptamer‐mediated interference of HCV replication by targeting the CRE‐5BSL3.2 domain
Marton, S., Romero‐López, C., & Berzal‐Herranz, A. (2012) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2012.01629.x · Cited by 19
Treatment of Hepatitis C in Potential Lung Transplant Candidates
Doucette, K. E., Weinkauf, J. G., Sumner, S., Ens, K., & Lien, D. C. (2007) · Transplantation · doi:10.1097/01.tp.0000264561.18380.22 · Cited by 19
Resource Utilization and Direct Medical Costs of Chronic Hepatitis C in Thailand: A Heavy but Manageable Economic Burden
Thongsawat, S., Piratvisuth, T., Pramoolsinsap, C., Chutaputti, A., Tanwandee, T., & Thongsuk, D. (2013) · Value in Health Regional Issues · doi:10.1016/j.vhri.2013.09.002 · Cited by 19
Role of Erythrocytes as a Reservoir for Ribavirin and Relationship with Adverse Reactions in the Early Phase of Interferon Combination Therapy for Chronic Hepatitis C Virus Infections
Saito, H., Tada, S., Ebinuma, H., Ishii, H., Kashiwazaki, K., Takahashi, M., Tsukada, N., Nishida, J., Tanaka, S., Shiozaki, H., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00079-06 · Cited by 19
CURRENT AND FUTURE THERAPIES OF HEPATITIS C
Shad, J. A., & McHutchison, J. G. (2001) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70169-0 · Cited by 19
Synthesis of 2-C-hydroxymethylribofuranosylpurines as potent anti-hepatitis C virus (HCV) agents
Yoo, B. N., Kim, H. O., Moon, H. R., Seol, S. K., Jang, S. K., Lee, K. M., & Jeong, L. S. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.05.089 · Cited by 19
Ribavirin with or without alpha interferon for chronic hepatitis C
Gluud, L. L., Krogsgaard, K., & Gluud, C. N. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002234.pub2 · Cited by 19
Modelling the transmission dynamics of HIV/AIDS and hepatitis C virus co-infection
Bhunu, C. P., & Mushayabasa, S. (2013) · HIV & AIDS Review · doi:10.1016/j.hivar.2013.03.001 · Cited by 18
Safety and efficacy ofHansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children
Naghi, S. E. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i16.4681 · Cited by 19
A Public Health Approach to Hepatitis C in an Urban Setting
Laraque, F., & Varma, J. K. (2017) · American Journal of Public Health · doi:10.2105/ajph.2017.303718 · Cited by 19
Psychological Disorders and Quality of Life Among Patients With Chronic Viral Hepatitis
Fotos, N. V., Elefsiniotis, I. S., Patelarou, A. E., Giakoumidakis, K., Patelarou, E., Kouros, A., & Brokalaki, H. (2018) · Gastroenterology Nursing · doi:10.1097/sga.0000000000000339 · Cited by 18
Decorin and actin expression and distribution in patients with chronic hepatitis C following interferon-alfa-2b treatment
Jármay, K., Gallai, M., Karácsony, G., Ozsvár, Z., Schaff, Z., Lonovics, J., & Kovalszky, I. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80104-x · Cited by 18
Intragraft localization of activated nuclear factor κB in recurrent hepatitis C virus disease following liver transplantation
Gaweco, A. S., Wiesner, R. H., Porayko, M. K., Rustgi, V. K., Yong, S. L., Hamdani, R., Harig, J. M., Chejfec, G., McClatchey, K. D., & Thiel, D. H. V. (2000) · Hepatology · doi:10.1053/he.2000.6983 · Cited by 18
Psychiatric Implications of Hepatitis-C Infection
Giunta, B. N., Somboonwit, C., Nikolic, W. V., Rrapo, E., Tan, J. R., Shapshak, P., & Fernandez, F. (2007) · Critical Reviews in Neurobiology · doi:10.1615/critrevneurobiol.v19.i2-3.20 · Cited by 18
Antimicrobial‐Associated Acute Hepatitis
Nicholson, S., Webb, C. D., & Moellering, R. C. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.9.794.34066 · Cited by 18
The design of potent, non-peptidic inhibitors of hepatitis C protease
Andrews, D. M., Chaignot, H. M., Coomber, B. A., Dowle, M. D., Hind, S. L., Johnson, M. R., Jones, P. S., Mills, G., Patikis, A. N., Pateman, T. J., et al. (2003) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(03)00050-3 · Cited by 18
Relationship between Regulatory T Cells and the Combination of Pegylated Interferon and Ribavirin for the Treatment of Chronic Hepatitis Type C
Akiyama, M., Ichikawa, T., Miyaaki, H., Motoyoshi, Y., Takeshita, S., Ozawa, E., Miuma, S., Shibata, H., Taura, N., & Nakao, K. (2010) · Intervirology · doi:10.1159/000274976 · Cited by 17
Risk factors of hepatitis C virus transmission and genotype distribution in former blood donors from Chinese rural area
Yin, W., Huang, C., Qiu, F., Liu, L., Wang, F., Zhou, J., Zhang, Y., & Bi, S. (2015) · BMC Public Health · doi:10.1186/s12889-015-1535-6 · Cited by 17
Prognosis of hepatitis C virus‐infected Canadian post‐transfusion compensation claimant cohort
Thein, H., Yi, Q., Heathcote, E. J., & Krahn, M. D. (2009) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2009.01136.x · Cited by 17
Inhibition of HCV subgenomic replicons by siRNAs derived from plasmids with opposing U6 and H1 promoters
Korf, M., Meyer, A., Jarczak, D., Beger, C., Manns, M. P., & Krüger, M. (2006) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2006.00793.x · Cited by 17
The patient's perspective in hepatitis C†
Fontana, R. J., & Kronfol, Z. (2004) · Hepatology · doi:10.1002/hep.20190 · Cited by 17
Recent advances in prevention and treatment of hepatitis C virus infections
Wang, Q. M., & Heinz, B. A. (2000) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8385-6_1 · Cited by 17
Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 Urea Leads to Potent Intracellular Inhibitors of Hepatitis C Virus NS3/4A Protease
Slater, M. J., Amphlett, E. M., Andrews, D. M., Bamborough, P., Carey, S. J., Johnson, M. R., Jones, P. S., Mills, G., Parry, N. R., Somers, D. O., et al. (2003) · Organic Letters · doi:10.1021/ol035826v · Cited by 17
Hepatitis C virus transmission in the hemodialysis community
Saab, S. (2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(05)80024-1 · Cited by 17
Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease
Slater, M. J., Andrews, D. M., Baker, G. R., Saalau-Bethell, S. M., Carey, S. J., Chaignot, H. M., Clarke, B. E., Coomber, B. A., Ellis, M., Good, A. C., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00789-8 · Cited by 17
Detailed analysis of the E2–IgM complex in hepatitis C‐related type II mixed cryoglobulinaemia
Ferri, S., Pero, F. D., Bortoletto, G., Bianchi, F. B., Lenzi, M., Alberti, A., & Gerotto, M. (2005) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2005.00675.x · Cited by 16
Influence of human t-cell lymphotropic virus type 1 (HTLV-1) Infection on laboratory parameters of patients with chronic hepatitis C virus
Cardoso, D. F., de Souza, F. V., Fonseca, L. A. M., Duarte, A. J. D. S., & Casseb, J. (2009) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s0036-46652009000600003 · Cited by 16
Ultrasensitive nanowire-based detection of HCVcoreAg in the serum using a microwave generator
Malsagova, K. A., Pleshakova, T. O., Galiullin, R. A., Kaysheva, A. L., Shumov, I. D., Ilnitskii, M. A., Popov, V. P., Glukhov, A. V., Archakov, A. I., & Ivanov, Y. D. (2018) · Analytical Methods · doi:10.1039/c8ay00495a · Cited by 16
A novel T cell evasion mechanism in persistent RNA virus infection.
Stapleton, J. T., Xiang, J., McLinden, J. H., Bhattarai, N., Chivero, E. T., Klinzman, D., Kaufman, T. M., & Chang, Q. (2014) · PubMed Central · Cited by 16
Catalytic RNase P RNA from Synechocystis sp. cleaves the hepatitis C virus RNA near the AUG start codon
Sabariegos, R., Nadal, A., Beguiristain, N., Pirón, M., & Gómez, J. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.10.059 · Cited by 16
Seroprevalence of Hepatitis C Virus Infection and Evaluation of Serum Aminotransferase Levels among Haemodialysis Patients in Izmir, Turkey
Olut, A., Özsakarya, F., & Dilek, M. (2005) · Journal of International Medical Research · doi:10.1177/147323000503300605 · Cited by 16
Long-Term Outcome of Acute Hepatitis B and C in an Outbreak of Hepatitis in 1969-72
Bläckberg, J., Braconier, J. H., Widell, A., & Kidd‐Ljunggren, K. (2000) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960050004 · Cited by 16

Authors: Hoofnagle, J. H.
Affiliations: National Institutes of Health (US)
Corresponding author: Hoofnagle, J H
Venue: Hepatology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1997-12
Volume: 26
Issue: Supplement 3
Pages: 15S-20S
ISSN: 0270-9139 (ISSN-L)
DOI: 10.1002/hep.510260703
OpenAlex: W1979931682
Cited by: 765
References: 47
Citations by year: 2026: 3 · 2025: 8 · 2024: 11 · 2023: 8 · 2022: 8 · 2021: 14 · 2020: 9 · 2019: 10 · 2018: 14 · 2017: 11 · 2016: 25 · 2015: 20 · 2014: 32 · 2013: 26 · 2012: 20
FWCI: 27.00
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6483 d)
Locations: Hepatology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hepatology › Hepatitis C virus research
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Keywords: hepatitis C, hepatitis C virus, acute hepatitis C, chronic hepatitis C, end-stage liver disease, liver cirrhosis, hepatocellular carcinoma, extrahepatic manifestations, cryoglobulinemia, glomerulonephritis, aminotransferase elevation, HCV RNA, incubation period, clinical spectrum
MeSH terms: Acute Disease, Transaminases, Chronic Disease, Hepatitis C, Humans, Severity of Illness Index, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Hepatitis C: the clinical spectrum of disease.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks